JP2014527802A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014527802A5 JP2014527802A5 JP2014528901A JP2014528901A JP2014527802A5 JP 2014527802 A5 JP2014527802 A5 JP 2014527802A5 JP 2014528901 A JP2014528901 A JP 2014528901A JP 2014528901 A JP2014528901 A JP 2014528901A JP 2014527802 A5 JP2014527802 A5 JP 2014527802A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- variable region
- chain variable
- humanized antibody
- humanized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004965 antibodies Human genes 0.000 claims description 9
- 108090001123 antibodies Proteins 0.000 claims description 9
- 102000009490 IgG Receptors Human genes 0.000 claims description 2
- 108010073807 IgG Receptors Proteins 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 102000005614 monoclonal antibodies Human genes 0.000 claims 3
- 108010045030 monoclonal antibodies Proteins 0.000 claims 3
- 210000001519 tissues Anatomy 0.000 claims 3
- 238000002054 transplantation Methods 0.000 claims 3
- 230000001404 mediated Effects 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 238000006011 modification reaction Methods 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000015434 Humanized Monoclonal Antibodies Human genes 0.000 claims 1
- 108010064750 Humanized Monoclonal Antibodies Proteins 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000002131 composite material Substances 0.000 claims 1
- 125000003147 glycosyl group Chemical group 0.000 claims 1
- 230000003899 glycosylation Effects 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000000056 organs Anatomy 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 101710044656 FCGR3A Proteins 0.000 description 3
- 102100015541 FCGR3A Human genes 0.000 description 3
- 101710044657 FCGR3B Proteins 0.000 description 2
- 101700009480 Fcgr3 Proteins 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000013135 CD52 Antigen Human genes 0.000 description 1
- 108010065524 CD52 Antigen Proteins 0.000 description 1
- 101710003435 FCGRT Proteins 0.000 description 1
- 102100014838 FCGRT Human genes 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000038129 antigens Human genes 0.000 description 1
- 108091007172 antigens Proteins 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000001809 detectable Effects 0.000 description 1
- 230000000275 pharmacokinetic Effects 0.000 description 1
Description
S298N/Y300S 2C3変異体は、CD52ペプチドにしっかりと結合し、結合のセンサーグラムが野生型対照と区別できないことから、このFcドメインにおける突然変異は、その抗原結合に影響を与えないことが示唆される(図26A)。
Fcのエフェクター機能をアッセイするために、結合研究にFcγRIII受容体(Val158)を使用した。突然変異体および野生型対照抗体を200nMに希釈し、HPC4−タグで捕捉したFcγRIIIaに注入した。FcγRIII結合は、S298N/Y300S突然変異体ではほとんど検出できなかったが、これは、この変異体はエフェクター機能を喪失したことを示す(図26B)。またこの突然変異体は、野生型抗体対照と同じ親和性でFcRn受容体にも結合したことから、発明者等は、その循環半減期またはその他の薬物動態学的特性は変化しないと予想する。(図26Cを参照)。発明者等は、例えばヒトFcγ受容体のエンゲージメントにより望ましくないFcのエフェクター機能を減少させたりまたは除去したりするために、S298N/Y300S突然変異は一般的に抗体に適用が可能であると結論付けた。
Fcのエフェクター機能をアッセイするために、結合研究にFcγRIII受容体(Val158)を使用した。突然変異体および野生型対照抗体を200nMに希釈し、HPC4−タグで捕捉したFcγRIIIaに注入した。FcγRIII結合は、S298N/Y300S突然変異体ではほとんど検出できなかったが、これは、この変異体はエフェクター機能を喪失したことを示す(図26B)。またこの突然変異体は、野生型抗体対照と同じ親和性でFcRn受容体にも結合したことから、発明者等は、その循環半減期またはその他の薬物動態学的特性は変化しないと予想する。(図26Cを参照)。発明者等は、例えばヒトFcγ受容体のエンゲージメントにより望ましくないFcのエフェクター機能を減少させたりまたは除去したりするために、S298N/Y300S突然変異は一般的に抗体に適用が可能であると結論付けた。
Claims (11)
- 配列番号7、12、13、15および16に記載の配列からなる群より選択されるアミ
ノ酸配列を有する重鎖可変領域と配列番号14に記載のアミノ酸配列を含む軽鎖可変領域を含む、ヒトαβTCR/CD3複合体に特異的なヒト化モノクローナル抗体。 - 重鎖可変領域が、配列番号7、配列番号12、および配列番号13に記載のアミノ酸配列からなる群より選択される、請求項1に記載のヒト化モノクローナル抗体。
- 重鎖可変領域が、配列番号15および配列番号16に記載のアミノ酸配列からなる群より選択される、請求項1に記載のヒト化モノクローナル抗体。
- ヒト由来の定常領域をさらに含む、請求項1〜3のいずれか1項に記載のヒト化抗体。
- Fcγ受容体結合を減少させるFc改変をさらに含む、請求項4に記載のヒト化抗体。
- 改変されたグリコシル化パターンを含む、請求項5に記載のヒト化抗体。
- 非グリコシル型Fc領域またはデルタab改変を含む、請求項5に記載のヒト化抗体。
- 請求項1〜7のいずれか1項に記載のヒト化モノクローナル抗体の、少なくとも1つの重鎖可変領域および軽鎖可変領域をコードする核酸。
- 請求項8に記載の核酸を発現する細胞。
- 対象におけるT細胞媒介応答を抑制するのに使用するための、請求項1〜7のいずれか1項に記載のヒト化抗体。
- T細胞媒介応答が、固形臓器移植および複合組織移植を含めた組織移植、組織グラフト、多発性硬化症、ならびに1型糖尿病からなる群より選択される状態に関連する、請求項10に記載の使用のためのヒト化抗体。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161533510P | 2011-09-12 | 2011-09-12 | |
US61/533,510 | 2011-09-12 | ||
PCT/EP2012/003819 WO2013037484A2 (en) | 2011-09-12 | 2012-09-12 | Anti-aplhabetatcr antibody |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017024560A Division JP6599911B2 (ja) | 2011-09-12 | 2017-02-14 | 抗αβTCR抗体 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2014527802A JP2014527802A (ja) | 2014-10-23 |
JP2014527802A5 true JP2014527802A5 (ja) | 2016-11-10 |
JP6096196B2 JP6096196B2 (ja) | 2017-03-15 |
Family
ID=46851393
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014528901A Active JP6096196B2 (ja) | 2011-09-12 | 2012-09-12 | 抗αβTCR抗体 |
JP2017024560A Active JP6599911B2 (ja) | 2011-09-12 | 2017-02-14 | 抗αβTCR抗体 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017024560A Active JP6599911B2 (ja) | 2011-09-12 | 2017-02-14 | 抗αβTCR抗体 |
Country Status (34)
Country | Link |
---|---|
US (3) | US10017573B2 (ja) |
EP (1) | EP2755999B1 (ja) |
JP (2) | JP6096196B2 (ja) |
KR (1) | KR20140072092A (ja) |
CN (2) | CN110272492A (ja) |
AU (2) | AU2012307816C1 (ja) |
BR (2) | BR112014005644A2 (ja) |
CA (1) | CA2847949C (ja) |
CL (2) | CL2014000574A1 (ja) |
CO (1) | CO6930307A2 (ja) |
CR (1) | CR20140127A (ja) |
DK (1) | DK2755999T3 (ja) |
DO (1) | DOP2014000052A (ja) |
EC (1) | ECSP14013307A (ja) |
ES (1) | ES2667893T3 (ja) |
GT (1) | GT201400045A (ja) |
HK (1) | HK1199268A1 (ja) |
HU (1) | HUE037470T2 (ja) |
IL (2) | IL231304B (ja) |
LT (1) | LT2755999T (ja) |
MA (1) | MA35711B1 (ja) |
MX (1) | MX355735B (ja) |
MY (1) | MY173924A (ja) |
NI (1) | NI201400019A (ja) |
PE (1) | PE20141548A1 (ja) |
PL (1) | PL2755999T3 (ja) |
PT (1) | PT2755999T (ja) |
RU (2) | RU2630656C2 (ja) |
SG (2) | SG10201601738UA (ja) |
TN (1) | TN2014000107A1 (ja) |
TW (1) | TWI593706B (ja) |
UA (1) | UA115533C2 (ja) |
UY (1) | UY34317A (ja) |
WO (1) | WO2013037484A2 (ja) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY34317A (es) | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
AU2013315499B2 (en) * | 2012-09-12 | 2018-08-09 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
US9790268B2 (en) | 2012-09-12 | 2017-10-17 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
BR112015020885A2 (pt) | 2013-03-11 | 2017-10-10 | Genzyme Corp | polipeptídeos de ligação hiperglicosilados |
EP3063174B1 (en) | 2013-10-30 | 2020-12-09 | Genzyme Corporation | Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide |
EP3129067B1 (en) | 2014-03-19 | 2023-01-04 | Genzyme Corporation | Site-specific glycoengineering of targeting moieties |
CA2964123C (en) | 2014-10-09 | 2023-09-05 | Genzyme Corporation | Glycoengineered antibody drug conjugates |
WO2016059220A1 (en) | 2014-10-16 | 2016-04-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Tcr-activating agents for use in the treatment of t-all |
CA2987877A1 (en) * | 2015-06-01 | 2016-12-08 | Medigene Immunotherapies Gmbh | T-cell receptor specific antibodies |
HRP20211744T1 (hr) | 2017-07-14 | 2022-02-04 | Immatics Biotechnologies Gmbh | Poboljšana molekula polipeptida dvostruke specifičnosti |
RU2708558C1 (ru) * | 2018-12-13 | 2019-12-09 | Российская Федерация, от имени которой выступает ФОНД ПЕРСПЕКТИВНЫХ ИССЛЕДОВАНИЙ | Способ создания противоопухолевой иммунологической защиты к клеткам лимфомы EL-4 |
AU2020253455A1 (en) | 2019-04-03 | 2021-11-04 | Genzyme Corporation | Anti-alpha beta TCR binding polypeptides with reduced fragmentation |
JP7137696B2 (ja) | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | 1型糖尿病を予防するための方法および組成物 |
EP4086341A1 (en) * | 2019-12-30 | 2022-11-09 | Edigene Biotechnology Inc. | Method for purifying ucart cell and use thereof |
CN113122503B (zh) * | 2019-12-30 | 2022-10-11 | 博雅缉因(北京)生物科技有限公司 | 一种靶向t细胞淋巴瘤细胞的通用型car-t及其制备方法和应用 |
CN113122504A (zh) * | 2019-12-30 | 2021-07-16 | 博雅辑因(北京)生物科技有限公司 | 一种纯化ucart细胞的方法与应用 |
CN113088495A (zh) * | 2020-01-09 | 2021-07-09 | 苏州方德门达新药开发有限公司 | 工程改造的t细胞、其制备及应用 |
WO2023227018A1 (zh) * | 2022-05-25 | 2023-11-30 | 羿尊生物医药(浙江)有限公司 | 靶向细胞膜受体蛋白的融合蛋白及其应用 |
Family Cites Families (122)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
US5149782A (en) | 1988-08-19 | 1992-09-22 | Tanox Biosystems, Inc. | Molecular conjugates containing cell membrane-blending agents |
DE68928427T2 (de) | 1988-09-15 | 1998-06-04 | Univ Columbia | Antikörper mit modifiziertem Kohlenhydratgehalt und Verfahren zur Herstellung und Verwendung |
US6780613B1 (en) | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
CA2018248A1 (en) | 1989-06-07 | 1990-12-07 | Clyde W. Shearman | Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
ATE297465T1 (de) | 1991-11-25 | 2005-06-15 | Enzon Inc | Verfahren zur herstellung von multivalenten antigenbindenden proteinen |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
EP0627932B1 (en) | 1992-11-04 | 2002-05-08 | City Of Hope | Antibody construct |
WO1994026087A2 (en) | 1993-05-14 | 1994-11-24 | Connor Kim C O | Recombinant protein production and insect cell culture and process |
US5429746A (en) | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
US5792456A (en) | 1994-08-04 | 1998-08-11 | Bristol-Myers Squibb Company | Mutant BR96 antibodies reactive with human carcinomas |
DK0706799T3 (da) | 1994-09-16 | 2002-02-25 | Merck Patent Gmbh | Immunkonjugater II |
GB9422383D0 (en) | 1994-11-05 | 1995-01-04 | Wellcome Found | Antibodies |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
WO1996040662A2 (en) | 1995-06-07 | 1996-12-19 | Cellpro, Incorporated | Aminooxy-containing linker compounds and their application in conjugates |
WO1997014719A1 (en) | 1995-10-16 | 1997-04-24 | Unilever N.V. | A bifunctional or bivalent antibody fragment analogue |
GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
SE9601245D0 (sv) | 1996-03-29 | 1996-03-29 | Pharmacia Ab | Chimeric superantigens and their use |
UA71889C2 (uk) | 1996-04-02 | 2005-01-17 | Йєда Рісерч Енд Дівелопмент Ко. Лтд. | Модулятори зв'язаного з рецептором tnf фактора (traf), їх одержання та застосування |
AU3968897A (en) | 1996-08-02 | 1998-02-25 | Bristol-Myers Squibb Company | A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis |
WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
AU759779B2 (en) | 1997-10-31 | 2003-05-01 | Genentech Inc. | Methods and compositions comprising glycoprotein glycoforms |
US6953675B2 (en) | 1997-11-06 | 2005-10-11 | Immunomedics, Inc. | Landscaped antibodies and antibody fragments for clinical use |
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
DK1068241T3 (da) | 1998-04-02 | 2008-02-04 | Genentech Inc | Antistofvarianter og fragmenter deraf |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
CA2341029A1 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
AU6059699A (en) | 1998-09-23 | 2000-04-10 | Regents Of The University Of California, The | Synthetic peptides, conjugation reagents and methods |
EP1006183A1 (en) | 1998-12-03 | 2000-06-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Recombinant soluble Fc receptors |
US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
ES2694002T3 (es) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polipéptido que comprende una región Fc de IgG1 humana variante |
US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
CN1110322C (zh) | 1999-07-21 | 2003-06-04 | 中国医学科学院医药生物技术研究所 | 单克隆抗体Fab'-平阳霉素偶联物及其抗肿瘤作用 |
EP1294904A1 (en) | 2000-06-30 | 2003-03-26 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Heterodimeric fusion proteins |
GB0029407D0 (en) | 2000-12-01 | 2001-01-17 | Affitech As | Product |
ES2649037T3 (es) | 2000-12-12 | 2018-01-09 | Medimmune, Llc | Moléculas con semividas prolongadas, composiciones y usos de las mismas |
US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
US20050107595A1 (en) | 2001-06-20 | 2005-05-19 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
US6900292B2 (en) | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US20040018557A1 (en) | 2002-03-01 | 2004-01-29 | Immunomedics, Inc. | Bispecific antibody point mutations for enhancing rate of clearance |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
CA2495251C (en) | 2002-08-14 | 2018-03-06 | Macrogenics, Inc. | Fc.gamma.riib-specific antibodies and methods of use thereof |
DK2345671T3 (en) | 2002-09-27 | 2016-02-15 | Xencor Inc | Optimized Fc variants and methods for their formation |
AU2003286467B2 (en) | 2002-10-15 | 2009-10-01 | Abbvie Biotherapeutics Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
JP2006524039A (ja) | 2003-01-09 | 2006-10-26 | マクロジェニクス,インコーポレーテッド | 変異型Fc領域を含む抗体の同定および作製ならびにその利用法 |
SI1641823T1 (sl) | 2003-06-12 | 2011-12-30 | Lilly Co Eli | Fuzijski proteini analogni glp-1 |
CN1871259A (zh) | 2003-08-22 | 2006-11-29 | 比奥根艾迪克Ma公司 | 具有改变的效应物功能的经改进的抗体和制备它的方法 |
RU2392324C2 (ru) * | 2003-09-18 | 2010-06-20 | Симфоген А/С | Способ связывания интересующих последовательностей |
GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
BR122018071968B8 (pt) | 2003-11-06 | 2021-07-27 | Seattle Genetics Inc | conjugado de anticorpo-droga, composição farmacêutica, artigo de manufatura e uso de um conjugado de anticorpo-droga |
EP1697415A1 (en) | 2003-11-12 | 2006-09-06 | Biogen Idec MA Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
US7001978B2 (en) | 2003-11-19 | 2006-02-21 | Xerox Corporation | Unsaturated ester substituted polymers with reduced halogen content |
EP1697741A4 (en) * | 2003-12-04 | 2008-02-13 | Xencor Inc | PROCESS FOR PRODUCING PROTEIN VARIANTS WITH INCREASED HOST STRUCTURE CONTENT AND COMPOSITIONS THEREOF |
EP1697520A2 (en) | 2003-12-22 | 2006-09-06 | Xencor, Inc. | Fc polypeptides with novel fc ligand binding sites |
US20080089892A1 (en) | 2004-01-12 | 2008-04-17 | Eli Lilly And Co. | Fc Region Variants |
EP1737890A2 (en) | 2004-03-24 | 2007-01-03 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
ATE455861T1 (de) | 2004-05-04 | 2010-02-15 | Novo Nordisk Healthcare Ag | O-verknüpfte glykoformen von faktor vii und verfahren zu deren herstellung |
WO2006085967A2 (en) | 2004-07-09 | 2006-08-17 | Xencor, Inc. | OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS |
EP2471813B1 (en) | 2004-07-15 | 2014-12-31 | Xencor, Inc. | Optimized Fc variants |
NZ580115A (en) | 2004-09-23 | 2010-10-29 | Genentech Inc | Cysteine engineered antibody light chains and conjugates |
US20060084145A1 (en) | 2004-09-27 | 2006-04-20 | Anderson Glenn M | sRAGE mimetibody, compositions, methods and uses |
WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
JP4829609B2 (ja) * | 2004-12-22 | 2011-12-07 | 独立行政法人科学技術振興機構 | ヒト抗体酵素およびその生産方法 |
ES2432091T5 (es) * | 2005-03-25 | 2022-03-18 | Gitr Inc | Moléculas de unión GITR y usos de las mismas |
AU2006230413B8 (en) | 2005-03-31 | 2011-01-20 | Xencor, Inc | Fc variants with optimized properties |
JP2008537941A (ja) | 2005-03-31 | 2008-10-02 | ゼンコー・インコーポレイテッド | 最適化特性を有するFc変異体 |
EP1896503B1 (en) | 2005-05-31 | 2014-10-29 | Board of Regents, The University of Texas System | IgG1 ANTIBODIES WITH MUTATED Fc PORTION FOR INCREASED BINDING TO FcRn RECEPTOR AND USES TEHEREOF |
ES2547463T3 (es) | 2005-06-17 | 2015-10-06 | Merck Sharp & Dohme Corp. | Moléculas de unión a ILT3 y usos de las mismas |
PT1896071E (pt) | 2005-06-30 | 2015-07-09 | Janssen Biotech Inc | Métodos e composições com melhorias na atividade terapêutica |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
CZ2005627A3 (cs) | 2005-10-03 | 2006-09-13 | Flek@Jaroslav | Zubní kartácek |
US7846724B2 (en) | 2006-04-11 | 2010-12-07 | Hoffmann-La Roche Inc. | Method for selecting CHO cell for production of glycosylated antibodies |
US7777008B2 (en) * | 2006-06-19 | 2010-08-17 | Tolerx, Inc. | ILT3 binding molecules and uses therefor |
CA2666308C (en) | 2006-10-26 | 2014-09-23 | The Rockefeller University | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
FI20060946A0 (fi) | 2006-10-26 | 2006-10-26 | Glykos Finland Oy | Influenssaviruksen nukleiinihappoja ja peptidejä |
PE20081250A1 (es) | 2006-11-28 | 2008-10-07 | Centelion | FUSIONES Fc CON RECEPTOR PARA FGF SOLUBLE MODIFICADAS, CON ACTIVIDAD BIOLOGICA MEJORADA |
AU2008205244B2 (en) * | 2007-01-09 | 2013-02-07 | Biogen Ma Inc. | Sp35 antibodies and uses thereof |
WO2008091954A2 (en) | 2007-01-23 | 2008-07-31 | Xencor, Inc. | Optimized cd40 antibodies and methods of using the same |
EP2144628B1 (en) | 2007-05-08 | 2012-10-17 | Genentech, Inc. | Cysteine engineered anti-muc16 antibodies and antibody drug conjugates |
US20100260751A1 (en) | 2007-09-28 | 2010-10-14 | Raju T Shantha | Methods and Structural Conformations of Antibody Preparations with Increased Resistance to Proteases |
EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
MX2010003718A (es) | 2007-10-19 | 2010-04-21 | Genentech Inc | Anticuerpos anti-tenb2 producidos por ingenieria de cisteina y conjugados de farmaco y anticuerpo. |
US20100286067A1 (en) | 2008-01-08 | 2010-11-11 | Biogenerix Ag | Glycoconjugation of polypeptides using oligosaccharyltransferases |
SI2247620T1 (sl) | 2008-01-31 | 2016-09-30 | Genentech, Inc. | Protitelesa proti CD79b in imunokonjugati in postopki za uporabo |
EP2268807A2 (en) | 2008-04-21 | 2011-01-05 | Novo Nordisk A/S | Hyperglycosylated human coagulation factor ix |
UA40611U (ru) | 2008-05-26 | 2009-04-27 | Владимир Семенович Живченко | Способ десульфурации железоуглеродистого расплава в тигельной печи |
CA2735193A1 (en) | 2008-08-26 | 2010-03-11 | Macrogenics, Inc. | T-cell receptor antibodies and methods of use thereof |
EP2233499A1 (en) | 2009-03-26 | 2010-09-29 | CSL Behring AG | Antibody composition with altered Fab sialylation |
US10087236B2 (en) | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
CA2791658C (en) | 2010-03-04 | 2019-10-01 | Macrogenics, Inc. | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
DK2603528T3 (en) | 2010-08-10 | 2016-11-28 | Glycotope Gmbh | FAB-glycosylated ANTIBODIES |
AR085302A1 (es) | 2011-02-24 | 2013-09-18 | Sanofi Sa | Metodo de produccion de anticuerpos sialilados |
SG193379A1 (en) | 2011-03-11 | 2013-10-30 | Amicus Therapeutics Inc | Dosing regimens for the treatment of fabry disease |
TWI743461B (zh) | 2011-03-28 | 2021-10-21 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
UY34317A (es) | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
US9790268B2 (en) | 2012-09-12 | 2017-10-17 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
AU2013315499B2 (en) | 2012-09-12 | 2018-08-09 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
BR112015020885A2 (pt) | 2013-03-11 | 2017-10-10 | Genzyme Corp | polipeptídeos de ligação hiperglicosilados |
EP3129067B1 (en) | 2014-03-19 | 2023-01-04 | Genzyme Corporation | Site-specific glycoengineering of targeting moieties |
WO2015157446A1 (en) | 2014-04-08 | 2015-10-15 | University Of Georgia Research Foundation Inc. | Site-specific antibody-drug glycoconjugates and methods |
CA2964123C (en) | 2014-10-09 | 2023-09-05 | Genzyme Corporation | Glycoengineered antibody drug conjugates |
US10280317B2 (en) | 2016-07-07 | 2019-05-07 | Northwestern University | Enhanced conductivity, adhesion and environmental stability of printed graphene inks with nitrocellulose |
-
2012
- 2012-09-10 UY UY0001034317A patent/UY34317A/es not_active Application Discontinuation
- 2012-09-12 ES ES12759019.8T patent/ES2667893T3/es active Active
- 2012-09-12 LT LTEP12759019.8T patent/LT2755999T/lt unknown
- 2012-09-12 CN CN201910265294.3A patent/CN110272492A/zh active Pending
- 2012-09-12 HU HUE12759019A patent/HUE037470T2/hu unknown
- 2012-09-12 JP JP2014528901A patent/JP6096196B2/ja active Active
- 2012-09-12 MY MYPI2014000458A patent/MY173924A/en unknown
- 2012-09-12 EP EP12759019.8A patent/EP2755999B1/en active Active
- 2012-09-12 US US14/241,099 patent/US10017573B2/en active Active
- 2012-09-12 BR BR112014005644A patent/BR112014005644A2/pt not_active Application Discontinuation
- 2012-09-12 WO PCT/EP2012/003819 patent/WO2013037484A2/en active Application Filing
- 2012-09-12 PT PT127590198T patent/PT2755999T/pt unknown
- 2012-09-12 CN CN201280055556.XA patent/CN104684930B/zh active Active
- 2012-09-12 PE PE2014000338A patent/PE20141548A1/es active IP Right Grant
- 2012-09-12 TW TW101133389A patent/TWI593706B/zh not_active IP Right Cessation
- 2012-09-12 DK DK12759019.8T patent/DK2755999T3/en active
- 2012-09-12 PL PL12759019T patent/PL2755999T3/pl unknown
- 2012-09-12 AU AU2012307816A patent/AU2012307816C1/en not_active Ceased
- 2012-09-12 MX MX2014002963A patent/MX355735B/es active IP Right Grant
- 2012-09-12 SG SG10201601738UA patent/SG10201601738UA/en unknown
- 2012-09-12 CA CA2847949A patent/CA2847949C/en not_active Expired - Fee Related
- 2012-09-12 BR BR122021001193-1A patent/BR122021001193B1/pt active IP Right Grant
- 2012-09-12 RU RU2014114527A patent/RU2630656C2/ru not_active IP Right Cessation
- 2012-09-12 SG SG11201400126PA patent/SG11201400126PA/en unknown
- 2012-09-12 RU RU2017129721A patent/RU2017129721A/ru not_active Application Discontinuation
- 2012-09-12 KR KR1020147009515A patent/KR20140072092A/ko not_active Application Discontinuation
- 2012-12-09 UA UAA201403678A patent/UA115533C2/uk unknown
-
2014
- 2014-03-04 IL IL231304A patent/IL231304B/en active IP Right Grant
- 2014-03-10 DO DO2014000052A patent/DOP2014000052A/es unknown
- 2014-03-10 CL CL2014000574A patent/CL2014000574A1/es unknown
- 2014-03-11 GT GT201400045A patent/GT201400045A/es unknown
- 2014-03-11 NI NI201400019A patent/NI201400019A/es unknown
- 2014-03-11 TN TNP2014000107A patent/TN2014000107A1/en unknown
- 2014-03-17 CR CR20140127A patent/CR20140127A/es unknown
- 2014-04-08 CO CO14075370A patent/CO6930307A2/es unknown
- 2014-04-11 EC ECSP14013307 patent/ECSP14013307A/es unknown
- 2014-04-11 MA MA36913A patent/MA35711B1/fr unknown
- 2014-12-22 HK HK14112798.3A patent/HK1199268A1/xx not_active IP Right Cessation
-
2017
- 2017-02-14 JP JP2017024560A patent/JP6599911B2/ja active Active
- 2017-06-29 CL CL2017001730A patent/CL2017001730A1/es unknown
- 2017-11-16 AU AU2017261557A patent/AU2017261557B2/en not_active Ceased
-
2018
- 2018-01-10 US US15/867,364 patent/US11186638B2/en active Active
- 2018-06-05 IL IL259826A patent/IL259826A/en unknown
-
2021
- 2021-10-26 US US17/511,218 patent/US20220153841A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2014527802A5 (ja) | ||
JP7089470B2 (ja) | 抗体およびその使用方法 | |
JP2018121657A5 (ja) | ||
Igawa et al. | Reduced elimination of IgG antibodies by engineering the variable region | |
JP2015535820A5 (ja) | ||
CY1120252T1 (el) | Μορια δεσμευσης αντιγονου με αυξημενη συγγενεια προσδεσης στον υποδοχεα fc και λειτουργια τελεστη | |
JP2014518883A5 (ja) | ||
WO2006082515A3 (en) | Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof | |
IN2015DN01361A (ja) | ||
NZ623319A (en) | Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
RU2014114172A (ru) | Легковыделяемые биспецифические антитела с природным иммуноглобулиновым форматом | |
JP2017505121A5 (ja) | ||
EP2444422A3 (en) | Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof | |
Mehta et al. | An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTA | |
JP2020500510A5 (ja) | ||
EP4342995A3 (en) | Methods for controlling blood pharmacokinetics of antibodies | |
AR084210A1 (es) | PROTEINAS DE UNION AL TNF-a | |
NZ628528A (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
JP2012515556A5 (ja) | ||
JP6391574B2 (ja) | 種間標的内交差反応性を有する抗体分子を産生する方法 | |
JP2012143232A5 (ja) | ||
JP2013538057A5 (ja) | ||
NZ706232A (en) | Anti-cd3 antibodies and uses thereof | |
JP2012531897A5 (ja) | ||
RU2015104760A (ru) | Связывающие kir3dl2 агенты |